Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04500847 · ClinicalTrials.gov registry record · Phase 1
Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD
A Phase 1 study of Mild Cognitive Impairment and Alzheimer Disease, Early Onset, sponsored by Butler Hospital.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 2
- Study locations
NCT04500847: Recruiting Phase 1 study of Mild Cognitive Impairment and Alzheimer Disease, Early Onset, sponsored by Butler Hospital.
NCT04500847 is a Phase 1 study of Mild Cognitive Impairment and Alzheimer Disease, Early Onset that is actively recruiting participants, run by Butler Hospital. The registered enrollment target is 35 participants, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04500847, a Phase 1 study of Mild Cognitive Impairment and Alzheimer Disease, Early Onset, is actively recruiting participants, sponsored by Butler Hospital.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a randomized, double-blind clinical trial of a daily oral dose of 200 mg emtricitabine vs. placebo in 35 participants with biomarker-confirmed MCI or mild to moderate dementia due to Alzheimer's disease. Study duration for each subject participating in the placebo-controlled research study will be approximately 12 months (up to a 3 months Screening Period, Baseline visit (1 month), 6 months of placebo or emtricitabine dosing, and 1 month follow-up). Participants will have up to 2 months to complete all procedures for the month 6 study visit.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Emtriva Capsule
Study Locations (2)
California
- Cedars-Sinai Medical Center - Los Angeles
Rhode Island
- Memory and Aging Program, Butler Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2021-12-17 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 1 |
What NCT04500847 shows while recruiting
NCT04500847 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (97% lower).
The record links to 3 conditions, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04500847 reports a single indexed study location in California, Rhode Island.
Frequently Asked Questions
What is clinical trial NCT04500847 about?
NCT04500847 is a clinical study titled "Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD". This is a randomized, double-blind clinical trial of a daily oral dose of 200 mg emtricitabine vs. placebo in 35 participants with biomarker-confirmed MCI or mild to moderate dementia due to Alzheimer's disease. Study duration for each subject participating in the placebo-controlled research study w...
What is the current status of trial NCT04500847?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2021-12-17. Estimated completion is 2026-03-31.
What conditions does trial NCT04500847 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment, Alzheimer Disease, Early Onset, Moderate Dementia.
What interventions are being tested in trial NCT04500847?
The interventions under investigation include: Placebo (DRUG), Emtriva Capsule (DRUG).
Who is sponsoring clinical trial NCT04500847?
This trial is sponsored by Butler Hospital, which has 103 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04500847 being conducted?
This trial has 2 study locations across California, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04500847's enrollment target sits among peer trials
35 158th of 205 higher than 46 of 205 other Mild Cognitive Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mild Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
rTMS to Improve Cognition in Parkinson's
RECRUITING · Phase 1
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
RECRUITING · Phase 1
-
Sense4Safety Intervention
RECRUITING · Phase 1
-
CogT pSOPT Intervention Study
RECRUITING · Phase 1
-
Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
RECRUITING · Phase 1
-
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI